Bristol-Myers Squibb Co. (BMY)

Bristol-Myers Squibb Co., adjusted current assets

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Current assets
	Adjustments
	Add: Bad debt allowances
	Less: Deferred income tax assets, current1
	After Adjustment
	Adjusted current assets

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).

Bristol-Myers Squibb Co., adjusted total assets

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Total assets
	Adjustments
	Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1
	Add: Bad debt allowances
	Less: Deferred income tax assets, current2
	Less: Deferred income tax assets, non-current3
	After Adjustment
	Adjusted total assets

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).

Bristol-Myers Squibb Co., adjusted current liabilities

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Current liabilities
	Adjustments
	Less: Deferred income tax liabilities, current (included in Liabilities related to assets held-for-sale or Income taxes payable)1
	Less: Deferred income, current portion
	Less: Restructuring liability, current
	After Adjustment
	Adjusted current liabilities

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).

Bristol-Myers Squibb Co., adjusted total liabilities

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Total liabilities
	Adjustments
	Add: Operating lease liability (before adoption of FASB Topic 842)1
	Less: Deferred income tax liabilities, current (included in Liabilities related to assets held-for-sale or Income taxes payable)2
	Less: Deferred income tax liabilities, non-current (included in Income taxes payable)3
	Less: Deferred income
	Less: Restructuring liability
	After Adjustment
	Adjusted total liabilities

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).

Bristol-Myers Squibb Co., adjusted total Bristol-Myers Squibb Company shareholders’ equity

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Total Bristol-Myers Squibb Company shareholders’ equity
	Adjustments
	Less: Deferred tax assets (liabilities), net1
	Add: Bad debt allowances
	Add: Deferred income
	Add: Restructuring liability
	Add: Noncontrolling interest
	After Adjustment
	Adjusted total Bristol-Myers Squibb Company shareholders’ equity

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).

Bristol-Myers Squibb Co., adjusted capitalization table

US$ in millions

		Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Short-term debt obligations
	Long-term debt, excluding current portion
	Total reported debt
	Total Bristol-Myers Squibb Company shareholders’ equity
	Total reported capital
	Adjustments to Debt
	Add: Operating lease liability (before adoption of FASB Topic 842)1
	Adjusted total debt
	Adjustments to Equity
	Less: Deferred tax assets (liabilities), net2
	Add: Bad debt allowances
	Add: Deferred income
	Add: Restructuring liability
	Add: Noncontrolling interest
	Adjusted total Bristol-Myers Squibb Company shareholders’ equity
	After Adjustment
	Adjusted total capital

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).

Bristol-Myers Squibb Co., adjusted revenues

US$ in millions

	12 months ended	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Revenues
	Adjustments
	Add: Increase (decrease) in deferred income
	After Adjustment
	Adjusted revenues

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).

Bristol-Myers Squibb Co., adjusted net earnings attributable to BMS

US$ in millions

	12 months ended	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
	As Reported
	Net earnings attributable to BMS
	Adjustments
	Add: Deferred income tax expense (benefit)1
	Add: Increase (decrease) in bad debt allowances
	Add: Increase (decrease) in deferred income
	Add: Increase (decrease) in restructuring liability
	Add: Other comprehensive income (loss)
	Add: Comprehensive income (loss), net of tax, attributable to noncontrolling interest
	After Adjustment
	Adjusted net earnings attributable to BMS

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).